Compare Ginkgo Bioworks Holdings Inc (DNA) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Philip Morris International Inc. — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while Philip Morris International Inc. trades at $176.99 (market cap $274.23B). The key difference: Philip Morris International Inc. is far larger — about 464.4× Ginkgo Bioworks Holdings Inc's market cap, and Philip Morris International Inc. pays a 3.34% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | PM | |
|---|---|---|
Market Cap | $590.53M | $274.23B |
Sector | Health | Consumer Staples |
52-Week High | $16.14 | $191.86 |
52-Week Low | $5.48 | $144.33 |
Enterprise Value | $627.78M | $320.73B |
Dividend Yield | — | 3.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Philip Morris International (PM) trades at $180.19, down 0.79% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $194.00. The company reported strong Q1 2026 EPS of $1.96, beating expectations, and maintains robust profitability with a 26.74% net income margin. Recent news includes a $500 million impairment charge in Q2 2026 and CFO succession plans, while cash flow trends show stable operations.
The stock presents a favorable risk-reward profile with upside to analyst targets, driven by earnings beats and brand strength, though risks include currency volatility, regulatory pressures, and consumer spending constraints highlighted in recent Reuters and WSJ reports. Long-term investors may find value in its dividend yield and market position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
